文献速递肾移植

C1酯酶抑制剂预防心脏死亡供肾移植后移植物功能延迟的三年结局:随机双盲安慰剂对照研究

Three-Year Outcomes of a Randomized, Double-Blind, Placebo-Controlled Study Assessing Safety and Efficacy of C1 Esterase Inhibitor for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients.
PubMed 文献 · Clin J Am Soc Nephrol · 2019-12-16

该研究为一项1/2期随机双盲安慰剂对照试验的事后分析,纳入70例有移植物功能延迟风险的心脏死亡供肾移植受者,术中及24小时给予C1酯酶抑制剂50 U/kg或安慰剂。结果显示C1酯酶抑制剂组移植物失败累积发生率低于安慰剂组(P=0.03),3.5年时eGFR较高,但C1酯酶抑制剂组有3例死亡而安慰剂组无死亡。

要点

  • C1酯酶抑制剂组3.5年移植物失败累积发生率显著低于安慰剂组(P=0.03)。
  • C1酯酶抑制剂组eGFR保持稳定,安慰剂组每年下降4 ml/min per 1.73 m2。
  • C1酯酶抑制剂组发生3例死亡,安慰剂组无死亡,需关注安全性。

核心结论

  • 对有缺血再灌注损伤和移植物功能延迟风险的患者,使用C1酯酶抑制剂与较低的移植物失败发生率相关。

研究设计与样本

  • 1/2期随机双盲安慰剂对照试验的事后分析,纳入70例心脏死亡供肾移植受者,随机接受C1酯酶抑制剂50 U/kg(n=35)或安慰剂(n=35),术中及24小时给药。

主要发现

  • C1酯酶抑制剂组发生3例死亡,安慰剂组无死亡。
  • 安慰剂组发生7例移植物失败,C1酯酶抑制剂组发生1例;3.5年移植物失败累积发生率C1酯酶抑制剂组更低(P=0.03)。
  • 两组eGFR斜率无显著差异(组别-时间交互P=0.12);安慰剂组eGFR每年下降4 ml/min per 1.73 m2(95%CI -8至-0.1),C1酯酶抑制剂组每年变化0.5 ml/min per 1.73 m2(95%CI -4至5)。
  • 3.5年时eGFR在C1酯酶抑制剂组为56 ml/min per 1.73 m2(95%CI 42至70),安慰剂组为35 ml/min per 1.73 m2(95%CI 21至48),估计平均差异为21 ml/min per 1.73 m2(95%CI 2至41)。

临床怎么用

  • 对于有移植物功能延迟风险的心脏死亡供肾移植受者,C1酯酶抑制剂可能降低移植物失败风险,但需警惕死亡事件。

局限性

  • 本研究为1/2期试验的事后分析,样本量较小(70例),结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Delayed graft function is related to ischemia-reperfusion injury and may be complement dependent. We previously reported from a randomized, placebo-controlled trial that treatment with C1 esterase inhibitor was associated with a shorter duration of delayed graft function and higher eGFR at 1 year. Here, we report longer-term outcomes from this trial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This is a post hoc analysis of a phase 1/2, randomized, controlled trial enrolling 70 recipients of deceased donor kidney transplants at risk for delayed graft function (NCT02134314). Subjects were randomized to receive C1 esterase inhibitor 50 U/kg (n=35) or placebo (n=35) intraoperatively and at 24 hours. The cumulative incidence functions method was used to compare graft failure and death over 3.5 years. eGFR slopes were compared using a linear mixed effects model. RESULTS: Three deaths occurred among C1 esterase inhibitor-treated patients compared with none receiving placebo. Seven graft failures developed in the placebo group compared with one among C1 esterase inhibitor-treated recipients; the cumulative incidence of graft failure was lower over 3.5 years among C1 esterase inhibitor-treated recipients compared with placebo (P=0.03). Although no difference in eGFR slopes was observed between groups (P for group-time interaction =0.12), eGFR declined in placebo-treated recipients (-4 ml/min per 1.73 m2 per year; 95% confidence interval, -8 to -0.1) but was stable in C1 esterase inhibitor-treated patients (eGFR slope: 0.5 ml/min per 1.73 m2 per year; 95% confidence interval, -4 to 5). At 3.5 years, eGFR was 56 ml/min per 1.73 m2 (95% confidence interval, 42 to 70) in the C1 esterase inhibitor group versus 35 ml/min per 1.73 m2 (95% confidence interval, 21 to 48) in the placebo group, with an estimated mean eGFR difference of 21 ml/min per 1.73 m2 (95% confidence interval, 2 to 41 ml/min per 1.73 m2). CONCLUSIONS: Treatment of patients at risk for ischemia-reperfusion injury and delayed graft function with C1 esterase inhibitor was associated with a lower incidence of graft failure.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Huang E, Vo A, Choi J, et al. Three-Year Outcomes of a Randomized, Double-Blind, Placebo-Controlled Study Assessing Safety and Efficacy of C1 Esterase Inhibitor for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2019. PMID: 31843975. doi:10.2215/CJN.04840419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。